Novo Nordisk announced today that Wegovy® (semaglutide injection) is now approved to reduce the risk of non-fatal myocardial ...

NOVO Nordisk on Wednesday announced that Wegovy (semaglutide injection) is now approved to reduce the risk of non-fatal ...

Subodh Verma, internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto ... with respect to reducing the incidence of three-point MACE consisting of cardiovascular ...

A STEMI is generally defined as an Electrocardiogram (EKG) with ST elevation of greater than 1 mm in 2 or more contiguous leads. It has also been defined as a "new" Left Bundle Branch Block (LBBB ...

According to this new report, the global cardiac biomarkers testing market is estimated to be valued at US$ 5.7 billion in the year 2028, growing at a CAGR of 8.5% in the period 2020 to 2028. Growth ...

According to this new report, the global cardiac biomarkers testing market is estimated to be valued at US$ 5.7 billion in the year 2028, growing at a CAGR of 8.5% in the period 2020 to 2028. Growth ...

Iga Swiatek, the world's number 2 tennis player, has received a one-month suspension for doping after testing positive for ...

Delve into the field of miRNA with 7 promising companies with miRNA-focused candidates in the pipeline, from oncology to ...

GLP-1 medications reduced the risk of major adverse cardiovascular events by 13% compared to a placebo, according to a study published Nov. 25 in The Lancet Diabetes & Endocrinology.

Results Seven neonates presented with cardiac failure within 17 days after birth requiring respiratory and circulatory support. Echocardiography showed dilatation and severe dysfunction of the left ...

Novo Nordisk said Wednesday that Wegovy is the first Health Canada-approved treatment for both chronic weight management and to reduce the risk of non-fatal myocardial infarction. The treatment ...